Equecabtagene Autoleucel

The "Relapsed Multiple Myeloma - Global Clinical Trials Review, 2024" report offers an overview of clinical trials worldwide, detailing trials by region, country, phase, status, and sponsor type, including prominent drugs and companies involved.

Innovent Biologics and Eli Lilly announce a Distribution and Promotion Agreement for Lilly's non-covalent BTK inhibitor, Jaypirca®, in Mainland China. Innovent will handle importation, marketing, distribution, and promotion, while Lilly will manage R&D and post-market medical affairs. Jaypirca®, approved by the U.S. FDA in January 2023 and China's NMPA in October 2024, is the first non-covalent BTK inhibitor for mantle cell lymphoma patients previously treated with covalent BTK inhibitors.

IASO Bio's Equecabtagene Autoleucel (Fucaso™) showed high efficacy and safety in treating relapsed/refractory multiple myeloma, with a 96% overall response rate and 74.3% stringent complete response/complete response rate, published in JAMA Oncology.

IASO Biotherapeutics presented a poster at the 2024 IMS Annual Meeting comparing outcomes of relapsed/refractory multiple myeloma patients treated with Eque-cel under different lymphodepletion regimens. Results showed full lymphodepletion significantly improved remission depth, duration, and progression-free survival without increased toxicity.